LWANC
ARQT icon

Laurel Wealth Advisors (North Carolina)’s Arcutis Biotherapeutics ARQT Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-440
Closed -$11K – 666
2021
Q3 		$11K Hold
440
– – ﹤0.01% 402
2021
Q2 		$12K Buy
+440
New +$12.4K ﹤0.01% 438

Other funds holding ARQT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s ARQT Position: Q4 2021 in Review

Laurel Wealth Advisors (North Carolina) sold out of Arcutis Biotherapeutics (ARQT) in Q4 2021, closing a stake of 440 shares — an estimated $11K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in ARQT in Q2 2021 and held it in 2 quarters. The position peaked at $12K in Q2 2021. 93 funds tracked by Wall St. Rank hold ARQT as of Q4 2021.

  • Laurel Wealth Advisors (North Carolina) reported no remaining Arcutis Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Laurel Wealth Advisors (North Carolina) sold 440 Arcutis Biotherapeutics shares in Q4 2021, an estimated $11K.
  • Laurel Wealth Advisors (North Carolina) first reported a position in Arcutis Biotherapeutics in Q2 2021 and held it in 2 quarters.
  • Laurel Wealth Advisors (North Carolina)'s Arcutis Biotherapeutics position peaked at $12K in Q2 2021.
  • 93 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2021.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q4 2021, filed 1 Feb 2022.